We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Hosted on MSN1mon
Coloplast targets 8%-9% organic growth for FY 2025 amid Kerecis expansion and new launchesEarnings Call Insights: Coloplast A/S (OTCPK:CLPBF) Q1 2025 CEO Kristian Villumsen highlighted 8% organic growth and a reported EBIT margin of 27% for Q1 2025, which aligned with expectations.
The global Urinary Incontinence Devices Market, valued at US$3.82 billion in 2023, is forecasted to grow at a robust CAGR of ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Coloplast delivered 8% organic growth and an EBIT margin1 of 27% in Q1, in line with expectations. Reported revenue in DKK grew 6% and included negative impact from the divestment of Skin Care and ...
Skin Barrier Products Market 2025 BURLINGAME, CA, UNITED STATES, March 11, 2025 /EINPresswire / --The Global Skin Barrier Products Mar ...
Coloplast (CSE: COLOb) has been upgraded to an "outperform" rating by RBC Capital Markets, with analysts citing a positive risk-reward balance and a price target increase to DKK 940 per share from DKK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback